Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia · 2026
Clinical, biochemical, and molecular spectrum of nephropathic cystinosis: Two novel CTNS mutations.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Abdallah Zeinab Youssef, Helmy Rasha, Nazim Walaa S, Nabhan Marwa M, Abdelaziz Hanan, Soliman Hala N, Saad Ahmed K, Ibrahim Mona, Gouda Amr Sobhi, Fateen Ekram, Soliman Neveen A
Аннотация
BACKGROUND: Nephropathic cystinosis (NC) is an autosomal recessive disease. Mutations in the CTNS gene encoding the lysosomal membrane cystine transporter cystinosin are identified as the molecular basis of cystinosis.
AIM: To evaluate the clinical phenotype, biochemical profile, and screen for mutations in CTNS genes in NC patients.
METHODS: Thirteen patients from 11 unrelated families were clinically suspected, for whom biochemical evaluation and screening of pathogenic CTNS gene mutations were performed.
RESULTS: Polymorphonuclear leukocyte cells leucocytes cystine assay range 4-13 nmol ½ cystine/mg proteins and median 5.5 nmol ½ cystine/mg proteins at follow up. Eight patients (66.6%) had high activity of chitotriosidase (101-417 umol/l/h, median 139.5), compared with normal subjects (4-80 nmol/l/h, mean 23 nmol/l/h). Value range was reduced to (56-175 umol/l/h, median 89) on treatment. Furthermore, two patients had high thyroid stimulating hormone level (36.1, 79. UI/ml), that normalized to (8.5, 6.4 UI/ml) during follow up. Nine pathogenic variants were identified in thirteen patients; two novel variants in two separate families, P111Rfs*7 and K335R, in exons 7 and 12, respectively, and seven known pathogenic variants.
CONCLUSION: Our study highlights the importance of close follow up of NC patients and expands the mutational spectrum of CTNS gene, as two novel mutations are identified in two unrelated families.
AIM: To evaluate the clinical phenotype, biochemical profile, and screen for mutations in CTNS genes in NC patients.
METHODS: Thirteen patients from 11 unrelated families were clinically suspected, for whom biochemical evaluation and screening of pathogenic CTNS gene mutations were performed.
RESULTS: Polymorphonuclear leukocyte cells leucocytes cystine assay range 4-13 nmol ½ cystine/mg proteins and median 5.5 nmol ½ cystine/mg proteins at follow up. Eight patients (66.6%) had high activity of chitotriosidase (101-417 umol/l/h, median 139.5), compared with normal subjects (4-80 nmol/l/h, mean 23 nmol/l/h). Value range was reduced to (56-175 umol/l/h, median 89) on treatment. Furthermore, two patients had high thyroid stimulating hormone level (36.1, 79. UI/ml), that normalized to (8.5, 6.4 UI/ml) during follow up. Nine pathogenic variants were identified in thirteen patients; two novel variants in two separate families, P111Rfs*7 and K335R, in exons 7 and 12, respectively, and seven known pathogenic variants.
CONCLUSION: Our study highlights the importance of close follow up of NC patients and expands the mutational spectrum of CTNS gene, as two novel mutations are identified in two unrelated families.